Amylin Pharmaceuticals, Inc. (AMLN) - Financial and Strategic SWOT Analysis Review

Amylin Pharmaceuticals, Inc. (AMLN) - Financial and Strategic SWOT Analysis Review

Summary

Amylin Pharmaceuticals, Inc. (Amylin Pharmaceuticals) is a biopharmaceutical company principally engaged in discovery, development and commercialization of medicines for the treatment of diabetes, obesity and other metabolic diseases. The marketed products of the company include BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection used for the treatment of diabetes. Its products are sold through a network of wholesale distributors. The products in company’s pipeline include BYDUREON and Metreleptin for diabetes and obesity treatment respectively. The major customers of the company are healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers and other third-party payers. The company is headquartered at San Diego in California, the US.

Amylin Pharmaceuticals, Inc. Key Recent Developments

Jul 26, 2011: Amylin Pharmaceuticals Reports Total Revenue Of $158.1m For Q2 2011
Jun 20, 2011: Amylin Pharmaceuticals To Present Promising New Data On Diabetes Programs At ADA 2011
Jun 08, 2011: US District Court Rules In Favor Of Lilly In Amylin Litigat

This comprehensive SWOT profile of Amylin Pharmaceuticals, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. SHOW LESS READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
Amylin Pharmaceuticals, Inc. - Key Facts
Amylin Pharmaceuticals, Inc. - Key Employees
Amylin Pharmaceuticals, Inc. - Key Employee Biographies
Amylin Pharmaceuticals, Inc. - Major Products and Services
Amylin Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data
Amylin Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Amylin Pharmaceuticals, Inc., Pipeline Products by Development Phase
Amylin Pharmaceuticals, Inc. - Medical Equipment Pipeline Products Data
Amylin Pharmaceuticals, Inc. Pipeline Products by Equipment Type
Amylin Pharmaceuticals, Inc. Pipeline Products by Development Stage
Amylin Pharmaceuticals, Inc. - History
Amylin Pharmaceuticals, Inc. - Company Statement
Amylin Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Amylin Pharmaceuticals, Inc. - Business Description
Amylin Pharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Amylin Pharmaceuticals, Inc. - Strengths
Strength - Exclusive products BYETTA and SYMLIN
Strength - Strategic Agreements
Strength - Strategic Focus on Metabolic Diseases
Weakness - Reliance on Third Parties
Weakness - High Debt-Equity Ratio
Weakness - Decline in Liquidity
Opportunity - Growing Market for Diabetes
Opportunity - Development of Metreleptin
Opportunity - Growing Market for Obesity Treatments
Opportunity - Entry into Biologics
Threat - Litigation
Threat - Intense Competition
Threat - Stringent Regulations
Amylin Pharmaceuticals, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Amylin Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Medical Equipment, Deals By Year, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Medical Equipment, Deals By Type, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 26, 2011: Amylin Pharmaceuticals Reports Total Revenue Of $158.1m For Q2 2011
Jun 20, 2011: Amylin Pharmaceuticals To Present Promising New Data On Diabetes Programs At ADA 2011
Jun 08, 2011: US District Court Rules In Favor Of Lilly In Amylin Litigation
May 16, 2011: Amylin Pharmaceuticals Files Lawsuit Against Eli Lilly
May 16, 2011: Lilly Provides Statement In Response To Amylin Lawsuit
Apr 18, 2011: Amylin Pharmaceuticals Reports Net Loss Of $37.3m For Q1 2011
Jan 26, 2011: Amylin Reports Net Loss Of $19.2 Million For Q4 2010
Nov 16, 2010: JDRF And Amylin Partner To Investigate Metreleptin
Nov 04, 2010: Amylin Reports Net Loss Of $50.7 Million For Q3 2010
Jul 21, 2010: Amylin Reports GAAP Net Loss Of $44.2 Million For Q2 2010
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Amylin Pharmaceuticals, Inc., Key Facts
Amylin Pharmaceuticals, Inc., Key Employees
Amylin Pharmaceuticals, Inc., Key Employee Biographies
Amylin Pharmaceuticals, Inc., Major Products and Services
Amylin Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area
Amylin Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage
Amylin Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase
Amylin Pharmaceuticals, Inc. Number of Pipeline Products by Equipment Type
Amylin Pharmaceuticals, Inc. Pipeline Products by Equipment Type
Amylin Pharmaceuticals, Inc. Number of Pipeline Products by Development Stage
Amylin Pharmaceuticals, Inc. Pipeline Products by Development Stage
Amylin Pharmaceuticals, Inc., History
Amylin Pharmaceuticals, Inc., Subsidiaries
Amylin Pharmaceuticals, Inc., Key Competitors
Amylin Pharmaceuticals, Inc., Ratios based on current share price
Amylin Pharmaceuticals, Inc., Annual Ratios
Amylin Pharmaceuticals, Inc., Interim Ratios
Amylin Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Medical Equipment, Deals By Year, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Medical Equipment, Deals By Type, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Amylin Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Amylin Pharmaceuticals, Inc., Pipeline Products by Development Phase
Amylin Pharmaceuticals, Inc. Pipeline Products by Equipment Type
Amylin Pharmaceuticals, Inc. Pipeline Products by Development Stage
Amylin Pharmaceuticals, Inc., Performance Chart (2006 - 2010)
Amylin Pharmaceuticals, Inc., Ratio Charts
Amylin Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Medical Equipment, Deals By Year, 2005 to YTD 2011
Amylin Pharmaceuticals, Inc., Medical Equipment, Deals by Type, 2005 to YTD 2011

Bristol-Myers Squibb Company
Merck & Co., Inc.
Novartis AG
GlaxoSmithKline
Santhera Pharmaceuticals Holding AG
Cytos Biotechnology AG
FunZyme BioTechnologies S.A.
Legacy Pharmaceuticals International